The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Apolipoprotein E genotype and mortality: findings from the Cache County Study.
Kathleen M Hayden; Peter P Zandi; Constantine G Lyketsos; JoAnn T Tschanz; Maria C Norton; Ara S Khachaturian; Carl F Pieper; Kathleen A Welsh-Bohmer; John C S Breitner; (Profiled Authors: Constantine Lyketsos; Peter Zandi; John Breitner)
Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina.
Journal of the American Geriatrics Society 2005;53(6):935-42.
OBJECTIVES: To evaluate the association between apolipoprotein E (apo E) epsilon4 and mortality, the population attributable risk for mortality with epsilon4, and relative contributions of cardiovascular disease (CVD) and Alzheimer's disease (AD). DESIGN: Population-based cohort study. SETTING: Community-based. PARTICIPANTS: Permanent residents of Cache County, Utah, aged 65 and older as of January 1, 1995. MEASUREMENTS: Participants were genotyped at the apo E locus using buccal-swab deoxyribonucleic acid. Cardiovascular health was ascertained using self- or proxy-report interviews at participants' residences. AD was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders criteria. Utah Department of Vital Statistics quarterly reports were reviewed to identify participants who died. RESULTS: Crude evaluations showed nonsignificantly greater risk of death for epsilon2/2 (hazard ratio (HR)=1.66, 95% confidence interval (CI)=0.92-2.76) and epsilon3/4 (HR=1.11, 95% CI=0.97-1.26) genotypes and significantly greater risk for epsilon4/4 (HR=1.48, 95% CI=1.09-1.96). After adjustment for age, age(2), sex, and education, risks increased to 1.98 (95% CI=1.08-3.35), 1.28 (95% CI=1.12-1.46), and 2.02 (95% CI=1.47-2.71), respectively, compared with epsilon3/3 genotypes. Adjustment for presence of any CVD did not change the risk of death for epsilon3/4 and epsilon4/4. Adjustment for AD reduced the risk of death for epsilon3/4 (HR=1.13, 95% CI=0.99-1.30) and epsilon4/4 (HR=1.59, 95% CI=1.15-2.14). The population attributable risk of death for epsilon3/4 and epsilon4/4 genotypes combined is estimated at 9.6%. CONCLUSION: These findings suggested that the epsilon2/2, epsilon3/4, and epsilon4/4 genotypes have greater early mortality risks. Further analyses showed that AD partially mediates the association between epsilon3/4, epsilon4/4, and death.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Ara S Khachaturian; Christopher D Corcoran; Lawrence S Mayer; Peter P Zandi; John C S Breitner;Archives of general psychiatry 2004;61(5):518-24.
Yi-Fang Chuang; Kathleen M Hayden; Maria C Norton; Joann Tschanz; John C S Breitner; Kathleen A Welsh-Bohmer; Peter P ZandiDementia and geriatric cognitive disorders 2010;29(3):248-53.
J C Breitner; B W Wyse; J C Anthony; K A Welsh-Bohmer; D C Steffens; M C Norton; J T Tschanz; B L Plassman; M R Meyer; I Skoog; et al.Neurology 1999;53(2):321-31.
Appears in this Publication
Author of this Publication